2025 Access Clinical Trials Patients 
Cannabis Law Report
NOVEMBER 16, 2021
As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients.
Cannabis Law Report
JANUARY 5, 2022
This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The patent will be issued on January 11, 2022. President, Director and Chief Medical Officer of MyMD.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 15, 2022
“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.
SMPL
MAY 26, 2020
Miller spent the months after this meeting leading hundreds of CBD seminars for farmers; Dr. Kerr began informal patient surveys to track how CBD made people feel; and as he finished his book, Mr. Lee often traveled around with Mr. Laughter and Mr. Ringo’s high-CBD plants and seeds, spreading the gospel at pot shops across the West.
Cannabis Law Report
OCTOBER 17, 2019
billion in 2025, according to Grandview Research. It’s big business,” says Jackim, noting that there are 200,000 patients in the state who hold cards allowing them to purchase cannabis for medical purposes. billion in 2018, and with a compound annual growth rate of 23.9%, is predicted to reach $66.3
Expert insights. Personalized for you.
52 
Let's personalize your content